WuXi Biologics (Cayman) Inc. (2269.HK)

13,480 +0,740 (+5,81%) Alla chiusura: 04:08PM HKT

WuXi Biologics (Cayman) Inc.

No. 108, Meiliang Road
Mashan
Wuxi 214092
China

https://www.wuxibiologics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 12.740

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ge Li Ph.D.	Founder & Chairman	N/D	N/D	1967
Dr. Zhisheng Chen	CEO & Executive Director	4,86M	N/D	1973
Dr. Weichang Zhou Ph.D.	Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director	3,27M	N/D	1964
Mr. Ming Tu	CFO & Executive VP	N/D	N/D	1968
Ms. Tang Shaogui M.B.A.	VP and Head of Global Communications, Operations & ESG	N/D	N/D	N/D
Dr. Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	N/D	N/D	1971
Dr. Jijie Gu	Executive VP & Chief Scientific Officer	N/D	N/D	1966
Ms. Eileen Wang	IR Senior Director	N/D	N/D	N/D
Ms. Cong Ding J.D.	VP & Head of Legal Department	N/D	N/D	N/D
He Wang	Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Governance aziendale

L'ISS Governance QualityScore di WuXi Biologics (Cayman) Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 10; diritti degli azionisti: 4; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.